No Detail Found!

Pharmacoeconomic evaluation of different doses of Curosurf for treating neonatal acute respiratory distress syndrome

Author(s)
Na Wang Department of Pediatrics, Wuhan No.1 Hospital,Wuhan,China
Lin Wang Department of Pediatrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan,China
Abstract
Neonatal acute respiratory distress syndrome (ARDS) is a serious stage of acute lung injury (ALI) which can be treated by exogenous surfactant. The aim of this study was to explore the clinical efficacy of two different doses of Poractant alfa (Curosurf®) for treating neonatal ARDS and to perform an economic evaluation. Fifty-four patients were divided into Group A (high dose) and Group B (low dose). Pharmacoeconomic evaluation was performed on the two groups regarding the treatment expenses, and the output was the cure rate and complication rate. There were significant differences between Group A and Group B for the duration of receiving oxygen therapy in moderate cases (6.4±3.5d:8.9±2.6d) (P0.05). A high dose of Curosurf had an advantage in treating neonatal ARDS, especially in severe cases, with lower final costs and better effects.
Publication Details
Page(s) 1139-1146
DOI DOI not available
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 33, Issue: 3, Year: 2020

Request the full text from PASTIC

0

Citations

0

Downloads

59

Views